JAK-IN-25

Cat. No.: HY-153440

CAS No.: 2127110-22-7

Molecular Formula: $C_{19}H_{17}N_5O_4$

Molecular Weight: 379.37

Target: JAK

Pathway: Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (13.18 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.6359 mL	13.1797 mL	26.3595 mL
5 mM	0.5272 mL	2.6359 mL	5.2719 mL
10 mM	0.2636 mL	1.3180 mL	2.6359 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC_{50}s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC_{50} of 28 nM. JAK-IN-25 has the potential for cancer research[1].

IC_{50} & Target

Tyk2	JAK1	JAK2	JAK3
6 nM (IC_{50})	21 nM (IC_{50})	8 nM (IC_{50})	1051 nM (IC_{50})

REFERENCES

[1]. Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA